ESMO 2021 Lung Cancer – Natasha B. Leighl
Natasha B. Leighl outlines recent insights gained in terms of circulating tumor DNA in patients with advanced NSCLC, the impact of liquid biopsy on the time to treatment, advantages of complementary testing, the clinical utility of plasma ctDNA testing in the context of treatment monitoring and future first-line treatment options for patients with advanced NSCLC.
Here is the full ESMO 2021 Lung Cancer report.
More posts
ATALANTE-1: anti-cancer vaccination after IO failure
ATALANTE-1: anti-cancer vaccination after IO failure OSE-2101 is an anti-cancer
Gradual progress in the management of mesothelioma and thymoma
Gradual progress in the management of mesothelioma and thymoma Oliver Gautschi,
Malignant pleural mesothelioma: immunotherapy-based approaches in all treatment lines
Malignant pleural mesothelioma: immunotherapy-based approaches in all treatment lin
Small-cell lung cancer: on the road to improved efficacy and tolerability
Small-cell lung cancer: on the road to improved efficacy and tolerability ATLAN
Immunotherapy: boosting efficacy and overcoming resistance
Immunotherapy: boosting efficacy and overcoming resistance POSEIDON: durvalumab
Innovative and established agents across a range of targets
Innovative and established agents across a range of targets Anti-HER2 treatment
